Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2013

01.08.2013 | original article

Relationship between hepcidin and ferritin in haemodialysed patients

verfasst von: Terezie Sedlackova, Ing, Prof. Jaroslav Racek, MUDr, DrSc, Daniel Rajdl, MUDr,PhD, Lukas Kielberger, MUDr, Jaromir Eiselt, Doc MUDr, PhD, Lada Malanova, MUDr, Vaclav Babuska, Ing. PhD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2013

Einloggen, um Zugang zu erhalten

Summary

Background

Hepcidin is a key regulator of iron metabolism. It binds to ferroportin and causes the trapping of iron in cells, rendering it unavailable for erythropoiesis. The synthesis of hepcidin is upregulated by high iron stores and inflammation. Haemodialysed patients suffer from anaemia and impaired iron management, the cause of which is multifactorial. Our aim was to describe the relationship between hepcidin and other parameters of iron metabolism, erythropoiesis, and inflammation.

Patients, materials and methods

Complete blood cell counts, hepcidin, parameters of iron metabolism, and inflammation were measured in samples from 164 dialysed patients and 37 control healthy volunteers. Patients were subdivided according to the time of dialysis session.

Results

According to the time of haemodialysis, iron levels showed an insignificant tendency for diurnal variability, whereas hepcidin levels were markedly different. Non-parametric correlations showed a weak, but statistically significant correlation between parameters of iron metabolism and inflammation in the entire group of patients. No correlation was found between hepcidin and other biochemical parameters in controls. Non-parametric correlations were also performed in the time subgroups of patients.

Conclusion

It seems that the influence of inflammation on hepcidin levels in haemodialysed patients is not crucial and other factors (e.g. hepcidin retention) are involved.
Literatur
1.
Zurück zum Zitat Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 2001;33:940–59.PubMedCrossRef Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 2001;33:940–59.PubMedCrossRef
2.
Zurück zum Zitat Tajima S, Ikeda Y, Sawada K, Yamano N, Horinouchi Y, Kihira Y, et al. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab. 2012;302:E77–86.PubMedCrossRef Tajima S, Ikeda Y, Sawada K, Yamano N, Horinouchi Y, Kihira Y, et al. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab. 2012;302:E77–86.PubMedCrossRef
3.
Zurück zum Zitat Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–8.PubMedCrossRef Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–8.PubMedCrossRef
4.
Zurück zum Zitat Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–10.PubMedCrossRef Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–10.PubMedCrossRef
5.
Zurück zum Zitat Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147–50.PubMedCrossRef Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147–50.PubMedCrossRef
6.
Zurück zum Zitat Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is over-expressed during iron overload. J Biol Chem. 2001;276:7811–9.PubMedCrossRef Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is over-expressed during iron overload. J Biol Chem. 2001;276:7811–9.PubMedCrossRef
7.
Zurück zum Zitat Bartnikas TB, Andrews NC, Fleming MD. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood. 2011;117:630–7.PubMedCrossRef Bartnikas TB, Andrews NC, Fleming MD. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood. 2011;117:630–7.PubMedCrossRef
8.
Zurück zum Zitat Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;DOI:10.1016/j.bbamcr.2012.01.014, in press. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;DOI:10.1016/j.bbamcr.2012.01.014, in press.
9.
Zurück zum Zitat Kemna EHJM, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem. 2007;53:620–8.PubMedCrossRef Kemna EHJM, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem. 2007;53:620–8.PubMedCrossRef
10.
Zurück zum Zitat Høyer K. Physiologic variations in the iron content of human blood serum. Acta Med Scand. 1944;119:562–76.CrossRef Høyer K. Physiologic variations in the iron content of human blood serum. Acta Med Scand. 1944;119:562–76.CrossRef
11.
Zurück zum Zitat Hamilton LD, Gubler CJ, Cartwright GE, Wintrobe MM. Diurnal variation in the plasma iron level of man. Proc Soc Exp Biol Med. 1950;75:65–8.PubMedCrossRef Hamilton LD, Gubler CJ, Cartwright GE, Wintrobe MM. Diurnal variation in the plasma iron level of man. Proc Soc Exp Biol Med. 1950;75:65–8.PubMedCrossRef
12.
Zurück zum Zitat Statland BE, Winkel P, Bokelund H. Variation of serum iron concentration in young healthy men: within-day and day-to-day changes. Clin Biochem. 1976;9:26–9.PubMedCrossRef Statland BE, Winkel P, Bokelund H. Variation of serum iron concentration in young healthy men: within-day and day-to-day changes. Clin Biochem. 1976;9:26–9.PubMedCrossRef
13.
Zurück zum Zitat Wiltink WF, Kruithof J, Mol C, Bos MG, Eijk HG van. Diurnal and nocturnal variations of the serum iron in normal subjects. Clin Chim Acta. 1973;49:99–104.PubMedCrossRef Wiltink WF, Kruithof J, Mol C, Bos MG, Eijk HG van. Diurnal and nocturnal variations of the serum iron in normal subjects. Clin Chim Acta. 1973;49:99–104.PubMedCrossRef
14.
Zurück zum Zitat Bowie EJ, Tauxe WN, Sjoberg WE Jr, Yamaguchi MY. Daily variation in the concentration of iron in serum. Am J Clin Pathol. 1963;40:491–4.PubMed Bowie EJ, Tauxe WN, Sjoberg WE Jr, Yamaguchi MY. Daily variation in the concentration of iron in serum. Am J Clin Pathol. 1963;40:491–4.PubMed
15.
Zurück zum Zitat Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–7.PubMedCrossRef Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–7.PubMedCrossRef
16.
Zurück zum Zitat Koch BCP, Nagtegaal JE, Kerkhof GA, ter Wee PM. Circadian sleep-wake rhythm disturbances in end-stage renal disease. Nat Rev Nephrol. 2009;5:407–16.PubMedCrossRef Koch BCP, Nagtegaal JE, Kerkhof GA, ter Wee PM. Circadian sleep-wake rhythm disturbances in end-stage renal disease. Nat Rev Nephrol. 2009;5:407–16.PubMedCrossRef
17.
Zurück zum Zitat Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75:976–81.PubMedCrossRef Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75:976–81.PubMedCrossRef
18.
Zurück zum Zitat Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance haemodialysis: role of inflammation. Am J Nephrol. 2010;31:534–40.PubMedCrossRef Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance haemodialysis: role of inflammation. Am J Nephrol. 2010;31:534–40.PubMedCrossRef
19.
Zurück zum Zitat Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009;39:883–90.PubMedCrossRef Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009;39:883–90.PubMedCrossRef
20.
Zurück zum Zitat Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, et al. Reduction of serum hepcidin by haemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol. 2010;5:1010–4.PubMedCrossRef Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, et al. Reduction of serum hepcidin by haemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol. 2010;5:1010–4.PubMedCrossRef
21.
Zurück zum Zitat Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, et al. Evaluation of hepcidin isoforms in haemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol. 2010;2010:329646.PubMedCrossRef Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, et al. Evaluation of hepcidin isoforms in haemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol. 2010;2010:329646.PubMedCrossRef
22.
Zurück zum Zitat Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108:1381–7.PubMedCrossRef Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108:1381–7.PubMedCrossRef
23.
Zurück zum Zitat Xu Y, Ding XQ, Zou JZ, Liu ZH, Jiang SH, Chen YM. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation. J Int Med Res. 2011;39:1961–7.PubMedCrossRef Xu Y, Ding XQ, Zou JZ, Liu ZH, Jiang SH, Chen YM. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation. J Int Med Res. 2011;39:1961–7.PubMedCrossRef
Metadaten
Titel
Relationship between hepcidin and ferritin in haemodialysed patients
verfasst von
Terezie Sedlackova, Ing
Prof. Jaroslav Racek, MUDr, DrSc
Daniel Rajdl, MUDr,PhD
Lukas Kielberger, MUDr
Jaromir Eiselt, Doc MUDr, PhD
Lada Malanova, MUDr
Vaclav Babuska, Ing. PhD
Publikationsdatum
01.08.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0388-1

Weitere Artikel der Ausgabe 15-16/2013

Wiener klinische Wochenschrift 15-16/2013 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Preisverleihung

mitteilungen der österreichischen gesellschaft für innere medizin

Die Österreichische Palliativgesellschaft (OPG)